Invest Like the Best

Capstan's next-generation in vivo CAR-T therapy—delivered by IV without extracting patient cells—is showing 100% tumor reduction in over 70% of patients, potentially obsoleting current manufacturing-intensive ex vivo CAR-T approaches.

AI drug discovery platforms have already compressed the target-to-candidate-molecule timeline from roughly two years to approximately one month, and this capability is commercially live today at companies such as Recursion.

The colorectal cancer blood-based screening market is inflecting, with Guardant Health's test gaining adoption beyond Exact Sciences' stool-based test; rising completion rates signal a consumer behavior shift toward proactive cancer detection.

Anti-amyloid Alzheimer's drugs from Biogen and Eli Lilly currently slow cognitive decline by 30% in late-stage patients; Karnal predicts early-intervention data expected later in 2025–2026 will likely show 50%+ reduction in Alzheimer's development.

Populations genetically deficient in PCSK9 protein show an 88% reduction in cardiovascular disease risk over 15 years; Karnal argues PCSK9 inhibitors have a more favorable risk-reward than GLP-1s and should ultimately be on more people with larger associated revenues.

GLP-1 consumers are optimizing for tolerability and modest health advantage—not maximum weight loss—meaning the market will favor lower-dose, lower-cost, durable formulations over high-efficacy blockbusters, contrary to Wall Street's conventional focus.

Oral semaglutide (Wegovy) launched at approximately $150/month ($1,800/year) is running at a 4x relative launch velocity versus Zepbound and has driven new weekly GLP-1 prescriptions from 200,000 to 300,000 within just a few months.

An estimated 15–20% of the addressable GLP-1 market was obtaining compounded versions at $200–250/month because they could not afford $400–500/month branded products, proving large price-sensitive demand that was previously invisible in prescription data.

Over half of new patients joining Eli Lilly's GLP-1 program are now entering via its direct-to-consumer digital channel rather than traditional physician rep networks, signaling a structural disruption in pharmaceutical distribution.

Novo Nordisk data demonstrates GLP-1 medicines provide greater than 20% reduction in heart attack and stroke risk independently of weight loss, indicating a direct cardioprotective biological mechanism.

Eli Lilly clinical data shows a 94% reduction in the risk of progressing from pre-diabetic to diabetic with GLP-1 medicines.

The GLP-1 drug class will easily exceed $100 billion in annual revenue, representing the first commercial proof of an impending trillion-dollar transformation in human health and annual healthcare cost savings.